0201 QT Deals
BioCentury & Getty Images


Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more  

Feb 2, 2021 | 2:36 AM GMT

Coherus BioSciences Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) partnered to co-develop Junshi’s PD-1 inhibitor Tuoyi toripalimab in the U.S. and Canada, with Coherus gaining exclusive commercialization

Read the full 599 word article

How to gain access

Continue reading with a
two-week free trial.